辐射损伤防护药及细胞因子治疗研究动态  

Status of the research on radioprotective drugs and treatment of radiation damage by cytokines

作　　者：闵锐[1] 

机构地区：[1]第二军医大学放射医学教研室,上海200433

出　　处：《国外医学（放射医学核医学分册）》2004年第4期173-178,共6页Foreign Medical Sciences(Section of Radiation Medicine and Nuclear Medicine)

摘　　要：硝基氧、氨磷汀和甾族类化合物是目前较受关注的防护辐射损伤的候选药,其中氨磷汀1999年已被美国FDA(食品与药物管理局)批准为放射治疗的辐射防护药。辐射损伤的细胞因子治疗已由过去单一造血细胞刺激因子的使用发展到针对多种造血细胞以及与造血及免疫细胞生长发育有关的微环境的不同功能因子的组合使用,大大改善了大剂量辐射损伤治疗的效果。Nitroxide, amifostine and steroids are most considered as candidates of radioprotective drug. Amifostine is the first radioprotective drug used in radiotherapy approved by FDA(Food and Drug Adminis-tration)of USA in 1999. The use of the cytokine in treatment of the radiation damage has been developed from single cytokine which just stimulates one cell population to the combination of cytokines which function as both hematopoitic cells and hematopoitic microenvironment. Therapeutic effect of radiation damage has been significantly improved by use of cytokine combination.

关 键 词：辐射损伤 辐射防护药 细胞因子 治疗 研究动态 

分 类 号：R818[医药卫生—放射医学]